Form 10-K - Annual report [Section 13 and 15(d), not S-K Item 405]:
SEC Accession No. 0000950170-25-034597
Filing Date
2025-03-06
Accepted
2025-03-06 16:05:31
Documents
96
Period of Report
2024-12-31

Document Format Files

Seq Description Document Type Size
1 10-K igms-20241231.htm   iXBRL 10-K 3796805
2 EX-4.1 igms-ex4_1.htm EX-4.1 67470
3 EX-10.3 igms-ex10_3.htm EX-10.3 508308
4 EX-19.1 igms-ex19_1.htm EX-19.1 189775
5 EX-23.1 igms-ex23_1.htm EX-23.1 3675
6 EX-31.1 igms-ex31_1.htm EX-31.1 17597
7 EX-31.2 igms-ex31_2.htm EX-31.2 18509
8 EX-32.1 igms-ex32_1.htm EX-32.1 9755
9 EX-32.2 igms-ex32_2.htm EX-32.2 9542
10 GRAPHIC img154019453_0.jpg GRAPHIC 214195
11 GRAPHIC img201892264_0.jpg GRAPHIC 833252
  Complete submission text file 0000950170-25-034597.txt   16789322

Data Files

Seq Description Document Type Size
12 XBRL TAXONOMY EXTENSION SCHEMA WITH EMBEDDED LINKBASES DOCUMENT igms-20241231.xsd EX-101.SCH 1671198
99 EXTRACTED XBRL INSTANCE DOCUMENT igms-20241231_htm.xml XML 2646363
Mailing Address 325 E MIDDLEFIELD ROAD MOUNTAIN VIEW CA 94043
Business Address 325 E MIDDLEFIELD ROAD MOUNTAIN VIEW CA 94043 650-965-7873
IGM Biosciences, Inc. (Filer) CIK: 0001496323 (see all company filings)

EIN.: 770349194 | State of Incorp.: DE | Fiscal Year End: 1231
Type: 10-K | Act: 34 | File No.: 001-39045 | Film No.: 25715195
SIC: 2834 Pharmaceutical Preparations
(CF Office: 03 Life Sciences)